Compare SKYT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | ORIC |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.8M | 783.0M |
| IPO Year | 2021 | 2020 |
| Metric | SKYT | ORIC |
|---|---|---|
| Price | $28.08 | $8.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $19.40 | ★ $19.73 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 02-25-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $346,587,000.00 | N/A |
| Revenue This Year | $28.48 | N/A |
| Revenue Next Year | $41.29 | N/A |
| P/E Ratio | $10.81 | ★ N/A |
| Revenue Growth | ★ 0.19 | N/A |
| 52 Week Low | $5.67 | $3.90 |
| 52 Week High | $28.73 | $14.93 |
| Indicator | SKYT | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 76.16 | 37.36 |
| Support Level | $18.15 | $7.84 |
| Resistance Level | $20.25 | $8.33 |
| Average True Range (ATR) | 1.82 | 0.44 |
| MACD | 1.17 | 0.11 |
| Stochastic Oscillator | 91.69 | 48.39 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.